Tissue factor and angiogenesis in cancer

Area of Science:

• Oncology
• Hematology
• Vascular Biology

Background:

• Idiopathic thrombosis can precede occult cancer diagnosis by years, suggesting a complex relationship.
• The interplay between coagulation initiator tissue factor (TF) and tumor angiogenesis is central to this unresolved paradigm.
• A vicious cycle of clot formation and tumor growth is known to exist.

Purpose of the Study:

• To review the latest research on tissue factor (TF) and angiogenesis.
• To highlight recent advancements in TF-targeted cancer therapeutics.
• To discuss potential complications of antiangiogenic therapy involving TF.

Main Methods:

• Literature review of recent studies on TF and angiogenesis.
• Analysis of TF-dependent and independent mechanisms of TF-induced angiogenesis.
• Examination of emerging TF-targeted cancer therapies and antiangiogenic treatment complications.

Main Results:

• TF plays a critical role in both initiating coagulation and promoting tumor angiogenesis through various pathways.
• Recent therapeutic strategies targeting TF have shown promise in preclinical and clinical settings.
• Antiangiogenic therapies may present unexpected complications potentially linked to TF.

Conclusions:

• The relationship between thrombosis and cancer is intricate, with TF as a key mediator.
• TF-targeted therapies represent a promising avenue for cancer treatment.
• Further research is needed to understand and mitigate TF-related complications in antiangiogenic therapy.